X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
empagliflozin (272) 272
index medicus (182) 182
type 2 diabetes (164) 164
humans (158) 158
diabetes (145) 145
double-blind (144) 144
diabetes mellitus, type 2 - drug therapy (134) 134
glucose (126) 126
endocrinology & metabolism (118) 118
dapagliflozin (116) 116
canagliflozin (100) 100
hypoglycemic agents - therapeutic use (99) 99
metformin (91) 91
safety (81) 81
sglt2 inhibitor (81) 81
sodium-glucose transporter 2 - antagonists & inhibitors (80) 80
dextrose (76) 76
diabetes mellitus (74) 74
type 2 diabetes mellitus (74) 74
glucosides - therapeutic use (73) 73
benzhydryl compounds - therapeutic use (69) 69
male (67) 67
pharmacology & pharmacy (66) 66
sglt2 inhibitors (65) 65
add-on (64) 64
glycemic control (63) 63
female (62) 62
clinical trials (59) 59
middle aged (59) 59
hypoglycemic agents - adverse effects (56) 56
efficacy (55) 55
analysis (53) 53
blood pressure (53) 53
sodium (53) 53
treatment outcome (52) 52
care and treatment (51) 51
aged (48) 48
diabetes mellitus, type 2 - blood (47) 47
add-on therapy (46) 46
hypoglycemic agents (46) 46
insulin (46) 46
internal medicine (45) 45
mellitus (45) 45
body weight (44) 44
diabetes therapy (44) 44
medicine & public health (44) 44
adult (43) 43
glucosides - adverse effects (43) 43
benzhydryl compounds - adverse effects (41) 41
inadequate glycemic control (40) 40
mortality (37) 37
glycosylated hemoglobin (36) 36
diabetes mellitus, type 2 - complications (35) 35
hyperglycemia (35) 35
hypoglycemia (35) 35
medicine, general & internal (35) 35
patients (35) 35
risk factors (35) 35
hypoglycemic agents - administration & dosage (34) 34
blood glucose - drug effects (33) 33
japanese patients (33) 33
monotherapy (33) 33
review (33) 33
cardiac & cardiovascular systems (32) 32
cardiology (32) 32
double-blind method (32) 32
glucosides - administration & dosage (32) 32
hypoglycemic agents - pharmacology (32) 32
blood-pressure (31) 31
hemoglobin (31) 31
type-2 diabetes-mellitus (31) 31
benzhydryl compounds - administration & dosage (30) 30
drug therapy (30) 30
drug therapy, combination (30) 30
sodium-glucose transporter 2 - metabolism (30) 30
cardiovascular diseases (29) 29
heart-failure (29) 29
pharmacokinetics (29) 29
placebo-controlled trial (29) 29
randomized controlled trials as topic (29) 29
blood glucose - metabolism (28) 28
heart failure (28) 28
risk (28) 28
medical research (27) 27
meta-analysis (27) 27
blood pressure - drug effects (26) 26
cardiovascular outcomes (26) 26
endocrinology (26) 26
hypoglycemia - chemically induced (26) 26
sitagliptin (25) 25
animals (24) 24
cardiovascular disease (24) 24
empagliflozin monotherapy (24) 24
inhibitors (24) 24
metformin plus sulfonylurea (24) 24
disease (22) 22
hypertension (22) 22
benzhydryl compounds - pharmacology (21) 21
glucose cotransporter 2 (21) 21
glucosides - pharmacology (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2017, Volume 19, Issue 5, pp. 721 - 728
Aims To conduct a phase III study to evaluate the efficacy and safety of ertugliflozin monotherapy in people with type 2 diabetes. Materials and methods This... 
type 2 diabetes mellitus | ertugliflozin | SGLT2 | monotherapy | INHIBITION | EVENTS | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | BLOOD-PRESSURE | EMPAGLIFLOZIN | Glycated Hemoglobin A - analysis | Mycoses - epidemiology | Overweight - drug therapy | Humans | Mycoses - microbiology | Anti-Obesity Agents - adverse effects | Male | Diabetes Mellitus, Type 2 - metabolism | Anti-Obesity Agents - therapeutic use | Incidence | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Immunity, Mucosal - drug effects | Overweight - metabolism | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Exercise | Hypoglycemic Agents - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Diabetes Mellitus, Type 2 - immunology | Reproductive Tract Infections - immunology | Diabetes Mellitus, Type 2 - therapy | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Reproductive Tract Infections - microbiology | Anti-Obesity Agents - administration & dosage | Double-Blind Method | Sodium-Glucose Transporter 2 - metabolism | Overweight - immunology | Reproductive Tract Infections - epidemiology | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Membrane Transport Modulators - administration & dosage | Combined Modality Therapy - adverse effects | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Overweight - therapy | Diet, Diabetic | Membrane Transport Modulators - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Mycoses - immunology | Diabetes
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 12/2015, Volume 14, Issue 1, p. 154
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 113 - 120
Aims To compare the efficacy and safety of dipeptidyl peptidase‐4 inhibitors (DPP‐4is) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) as monotherapy... 
dipeptidyl peptidase‐4 inhibitors | type 2 diabetes mellitus | sodium‐glucose cotransporter‐2 inhibitors | dipeptidyl peptidase-4 inhibitors | sodium-glucose cotransporter-2 inhibitors | INITIAL COMBINATION THERAPY | SAXAGLIPTIN | SITAGLIPTIN | AMERICAN-COLLEGE | ASIAN PATIENTS | INADEQUATE GLYCEMIC CONTROL | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | EMPAGLIFLOZIN MONOTHERAPY | CONSENSUS STATEMENT | Glycated Hemoglobin A - analysis | Overweight - complications | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Overweight - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Anti-Obesity Agents - adverse effects | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Overweight - prevention & control | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Membrane Transport Modulators - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Analysis | Glycosylated hemoglobin | Hypoglycemic agents | Glucose | Dextrose | Peptidase | Sodium | Diabetes mellitus | Body weight | Clinical trials | Hemoglobin | Systematic review | Diabetes | Safety | Metformin | Hypoglycemia
Journal Article
Life Sciences, ISSN 0024-3205, 09/2019, Volume 232, p. 116622
This study was designed to compare the effects of empagliflozin monotherapy and its combination with metformin on glucose and lipid modulations in T2DM mice.... 
Empagliflozin | T2DM mice | Combined therapy | Lipid and glucose metabolism | MEDICINE, RESEARCH & EXPERIMENTAL | ADD-ON | GLUCONEOGENESIS | SGLT2 INHIBITOR | PHARMACOLOGY & PHARMACY | AGENTS | INSULIN SENSITIVITY | Glucose metabolism | Therapy | Model matching | Homeostasis | Lipids | Mice | Lipid metabolism | Metformin | Divalent metal transporter-1 | Glucose | Metabolism | Lipoproteins (high density)
Journal Article
Advances in Therapy, ISSN 0741-238X, 6/2014, Volume 31, Issue 6, pp. 621 - 638
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 09/2018, Volume 34, Issue 9, pp. 1595 - 1603
Objective: Treatment intensification with additional anti-diabetic agents is recommended in type 2 diabetes (T2D) for patients inadequately controlled on... 
glucagon-like peptide-1 analog | SGLT-2 inhibitors | type 2 diabetes | GLP-1 | SUSTAIN 2 | SUSTAIN 7 | Once-weekly semaglutide | MEDICINE, RESEARCH & EXPERIMENTAL | GLYCEMIC CONTROL | PLACEBO | ADD-ON | DAPAGLIFLOZIN | SAFETY | BLOOD-PRESSURE | MEDICINE, GENERAL & INTERNAL | CANAGLIFLOZIN | DOUBLE-BLIND | WEIGHT | EMPAGLIFLOZIN
Journal Article
Journal Article
Journal Article
Indian Journal of Endocrinology and Metabolism, ISSN 2230-8210, 03/2017, Volume 21, Issue 2, pp. 286 - 292
Empagliflozin, a sodium glucose cotransporter-2 inhibitor, was recently evaluated in a randomized, controlled trial (RCT) in drug-naïve Type 2 diabetes... 
empagliflozin | Indian subgroup | type 2 diabetes | Drug naïve | Original
Journal Article
Journal Article